{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:58:24Z","timestamp":1778482704282,"version":"3.51.4"},"reference-count":283,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>While oral agents have been the gold standard for cardiovascular disease therapy, the new generation of treatments is switching to other administration options that offer reduced dosing frequency and more efficacy. The lymphatic network is a unidirectional and low-pressure vascular system that is responsible for the absorption of interstitial fluids, molecules, and cells from the peripheral tissue, including the skin and the intestines. Targeting the lymphatic route for drug delivery employing traditional or new technologies and drug formulations is exponentially gaining attention in the quest to avoid the hepatic first-pass effect. The present review will give an overview of the current knowledge on the involvement of the lymphatic vessels in drug delivery in the context of cardiovascular disease.<\/jats:p>","DOI":"10.3390\/pharmaceutics13081200","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T21:45:06Z","timestamp":1628113506000},"page":"1200","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine"],"prefix":"10.3390","volume":"13","author":[{"given":"Nolwenn","family":"Tessier","sequence":"first","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montreal, QC H3T 1J4, Canada"},{"name":"Montreal Heart Institute Research Center, Montreal, QC H1T 1C8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1451-9730","authenticated-orcid":false,"given":"Fatma","family":"Moawad","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universit\u00e9 de Montr\u00e9al, Montreal, QC H3T 1J4, Canada"},{"name":"Department of Pharmaceutics, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62511, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Amri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montreal, QC H3T 1J4, Canada"},{"name":"Montreal Heart Institute Research Center, Montreal, QC H1T 1C8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Brambilla","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Universit\u00e9 de Montr\u00e9al, Montreal, QC H3T 1J4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Martel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montreal, QC H3T 1J4, Canada"},{"name":"Montreal Heart Institute Research Center, Montreal, QC H1T 1C8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e1332","DOI":"10.1016\/S2214-109X(19)30318-3","article-title":"World Health Organization cardiovascular disease risk charts: Revised models to estimate risk in 21 global regions","volume":"7","author":"Kaptoge","year":"2019","journal-title":"Lancet Glob. Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics\u20142021 update: A report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/2230-973X.96920","article-title":"Drug delivery systems: An updated review","volume":"2","author":"Tiwari","year":"2012","journal-title":"Int. J. Pharm. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2014.04.051","article-title":"Nano-chemotherapeutics: Maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers","volume":"193","author":"Ryan","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.addr.2017.07.005","article-title":"Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges","volume":"114","author":"Maisel","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.addr.2011.05.018","article-title":"The role of the lymphatic system in vaccine trafficking and immune response","volume":"63","author":"Pal","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_7","first-page":"62","article-title":"The relationship between tumors and the lymphatics: What more is there to know?","volume":"39","author":"Sleeman","year":"2006","journal-title":"Lymphology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/(SICI)1520-6017(200003)89:3<297::AID-JPS2>3.0.CO;2-P","article-title":"Lymphatic transport of proteins after subcutaneous administration","volume":"89","author":"Porter","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"ref_9","first-page":"247","article-title":"Recent advances in lymphatic targeted drug delivery system for tumor metastasis","volume":"11","author":"Zhang","year":"2014","journal-title":"Cancer Biol. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.addr.2011.05.019","article-title":"Intestinal lymphatic transport for drug delivery","volume":"63","author":"Wang","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_11","unstructured":"Asellius, G. (1627). De Lactibus Sive Lacteis Venis, JB Bidellium."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/lrb.2008.1008","article-title":"The lymphatic system in health and disease","volume":"6","author":"Cueni","year":"2008","journal-title":"Lymphat. Res. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3389\/fphys.2020.00476","article-title":"Extracellular Vesicles as Potential Prognostic Markers of Lymphatic Dysfunction","volume":"11","author":"Milasan","year":"2020","journal-title":"Front. Physiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0003-4975(10)60949-6","article-title":"The role of lymphstasis in atherogenesis","volume":"31","author":"Lemole","year":"1981","journal-title":"Ann. Thorac. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1172\/JCI63685","article-title":"Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice","volume":"123","author":"Martel","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2019.01.031","article-title":"Early rescue of lymphatic function limits atherosclerosis progression in Ldlr\u2212\/\u2212 mice","volume":"283","author":"Milasan","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"eabc2697","DOI":"10.1126\/sciadv.abc2697","article-title":"Efficient aortic lymphatic drainage is necessary for atherosclerosis regression induced by ezetimibe","volume":"6","author":"Yeo","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cvr\/cvaa244","article-title":"Role of R-spondin 2 in arterial lymphangiogenesis and atherosclerosis","volume":"117","author":"Singla","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e006892","DOI":"10.1161\/JAHA.117.006892","article-title":"Apolipoprotein A-I Modulates Atherosclerosis Through Lymphatic Vessel-Dependent Mechanisms in Mice","volume":"6","author":"Milasan","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"fso 61","DOI":"10.4155\/fso.15.61","article-title":"Lymphatic network in atherosclerosis: The underestimated path","volume":"1","author":"Milasan","year":"2015","journal-title":"Future Sci. OA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"31427","DOI":"10.3402\/jev.v5.31427","article-title":"Extracellular vesicles are present in mouse lymph and their level differs in atherosclerosis","volume":"5","author":"Milasan","year":"2016","journal-title":"J. Extracell. Vesicles"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"27862","DOI":"10.1038\/srep27862","article-title":"Effects of LDL Receptor Modulation on Lymphatic Function","volume":"6","author":"Milasan","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1161\/CIRCULATIONAHA.115.020143","article-title":"Selective Stimulation of Cardiac Lymphangiogenesis Reduces Myocardial Edema and Fibrosis Leading to Improved Cardiac Function Following Myocardial Infarction","volume":"133","author":"Henri","year":"2016","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nature14483","article-title":"Cardiac lymphatics are heterogeneous in origin and respond to injury","volume":"522","author":"Klotz","year":"2015","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1172\/JCI97192","article-title":"The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction","volume":"128","author":"Vieira","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-34770-4","article-title":"Downregulation of VEGFR3 signaling alters cardiac lymphatic vessel organization and leads to a higher mortality after acute myocardial infarction","volume":"8","author":"Vuorio","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrd4608","article-title":"From sewer to saviour\u2014targeting the lymphatic system to promote drug exposure and activity","volume":"14","author":"Trevaskis","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7349","DOI":"10.2147\/IJN.S179678","article-title":"Nanotechnology, an alternative with promising prospects and advantages for the treatment of cardiovascular diseases","volume":"13","author":"Li","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4161\/self.1.3.12643","article-title":"Gene therapy in diabetes","volume":"1","author":"Wong","year":"2010","journal-title":"Self Nonself"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1517\/14712598.1.4.655","article-title":"Gene therapy for hypertension: Sense and antisense strategies","volume":"1","author":"Phillips","year":"2001","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/13543784.2020.1757070","article-title":"Gene-based therapy in lipid management: The winding road from promise to practice","volume":"29","author":"Tromp","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e012239","DOI":"10.1161\/JAHA.119.012239","article-title":"Current landscape of heart failure gene therapy","volume":"8","author":"Kieserman","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1517\/14712598.2014.912272","article-title":"Gene therapy for peripheral arterial disease","volume":"14","author":"Shimamura","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3389\/fbioe.2020.00880","article-title":"Drug Delivery System in the Treatment of Diabetes Mellitus","volume":"8","author":"Zhao","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1084\/jem.79.2.137","article-title":"Studies on the chemical nature of the substance inducing transformation of pneumococcal types: Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III","volume":"79","author":"Avery","year":"1944","journal-title":"J. Exp. Med."},{"key":"ref_37","first-page":"289","article-title":"Gene therapy for cardiovascular disease. Semin. Cardiothorac","volume":"4","author":"Meyerson","year":"2000","journal-title":"Vasc. Anesth."},{"key":"ref_38","first-page":"1","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"H629","DOI":"10.1152\/ajpheart.00126.2012","article-title":"Nonviral gene therapy targeting cardiovascular system","volume":"303","author":"Su","year":"2012","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ymthe.2017.01.024","article-title":"Polyplex Evolution: Understanding Biology, Optimizing Performance","volume":"25","author":"Hall","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1517\/14712598.2014.866085","article-title":"Cardiovascular gene therapy for myocardial infarction","volume":"14","author":"Scimia","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1161\/CIRCRESAHA.120.315855","article-title":"Gene therapy for the heart lessons learned and future perspectives","volume":"126","author":"Ali","year":"2020","journal-title":"Circ. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1161\/HYPERTENSIONAHA.118.11084","article-title":"Recent advances in therapeutic vaccines to treat hypertension","volume":"72","author":"Nakagami","year":"2018","journal-title":"Hypertension"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Siriwardena, A.N. (2012). Increasing Evidence That Influenza Is a Trigger for Cardiovascular Disease, Oxford University Press.","DOI":"10.1093\/infdis\/jis598"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1183\/09031936.00049111","article-title":"Is community-acquired pneumonia an independent risk factor for cardiovascular disease?","volume":"39","author":"Singanayagam","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3389\/fbioe.2019.00489","article-title":"Application of the Nano-Drug Delivery System in Treatment of Cardiovascular Diseases","volume":"7","author":"Deng","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Sezer, A.D. (2014). Application of Nanotechnology in Drug Delivery, BoD\u2013Books on Demand.","DOI":"10.5772\/57028"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Zhang, J., Xie, Z., Zhang, N., and Zhong, J. (2017). Nanosuspension drug delivery system: Preparation, characterization, postproduction processing, dosage form, and application. Nanostructures for Drug Delivery, Elsevier.","DOI":"10.1016\/B978-0-323-46143-6.00013-0"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jconrel.2015.07.033","article-title":"Micro\/nanofabricated platforms for oral drug delivery","volume":"219","author":"Fox","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s11095-010-0083-0","article-title":"The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623)","volume":"27","author":"Trevaskis","year":"2010","journal-title":"Pharm. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"105812","DOI":"10.1016\/j.ejps.2021.105812","article-title":"Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review","volume":"162","author":"Vinarov","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"254s","DOI":"10.18433\/jpps30217","article-title":"Lymphatic drug absorption via the enterocytes: Pharmacokinetic simulation, modeling, and considerations for optimal drug development","volume":"21","author":"Brocks","year":"2018","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0168-3659(94)90079-5","article-title":"Microparticulate absorption from the rat intestine","volume":"29","author":"Jenkins","year":"1994","journal-title":"J. Control. Release"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0378-5173(86)90027-X","article-title":"Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules","volume":"34","author":"Charman","year":"1986","journal-title":"Int. J. Pharm."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jcmgh.2018.12.002","article-title":"The Intestinal Lymphatic System: Functions and Metabolic Implications","volume":"7","author":"Cifarelli","year":"2019","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.1111\/j.1749-6632.2010.05708.x","article-title":"Microanatomy of the intestinal lymphatic system","volume":"1207","author":"Miller","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2337\/dc16-0614","article-title":"Risk of Cause-Specific Death in Individuals With Diabetes: A Competing Risks Analysis","volume":"39","author":"Subirana","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1007\/s00125-017-4336-x","article-title":"Metformin: Clinical use in type 2 diabetes","volume":"60","author":"Inzucchi","year":"2017","journal-title":"Diabetologia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"840","DOI":"10.5114\/aoms.2015.53304","article-title":"Sulfonylureas and their use in clinical practice","volume":"11","author":"Sola","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2147\/VHRM.S3119","article-title":"Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes","volume":"4","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11892-019-1270-y","article-title":"Thiazolidinediones: The Forgotten Diabetes Medications. Curr","volume":"19","author":"Lebovitz","year":"2019","journal-title":"Diabetes Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3389\/fendo.2019.00389","article-title":"Clinical Use of DPP-4 Inhibitors","volume":"10","author":"Gallwitz","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"E1128","DOI":"10.1503\/cmaj.190047","article-title":"Sodium-glucose cotransporter inhibitors in type 2 diabetes: Thinking beyond glucose lowering","volume":"191","author":"Neuen","year":"2019","journal-title":"CMAJ"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1021\/acs.molpharmaceut.8b00708","article-title":"Immense insulin intestinal uptake and lymphatic transport using bile acid conjugated partially uncapped liposome","volume":"15","author":"Kim","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2217\/nnm.12.31","article-title":"Folate-decorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin","volume":"7","author":"Jain","year":"2012","journal-title":"Nanomedicine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1809015","DOI":"10.1002\/adfm.201809015","article-title":"Phase-Changeable Nanoemulsions for Oral Delivery of a Therapeutic Peptide: Toward Targeting the Pancreas for Antidiabetic Treatments Using Lymphatic Transport","volume":"29","author":"Lin","year":"2019","journal-title":"Adv. Funct. Mater."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/bmj.2.3286.1204","article-title":"Insulin in alcoholic solution by the mouth","volume":"2","author":"Harrison","year":"1923","journal-title":"Br. Med. J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.biomaterials.2008.12.066","article-title":"In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery","volume":"30","author":"Sonaje","year":"2009","journal-title":"Biomaterials"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2011.12.055","article-title":"HP55-coated capsule containing PLGA\/RS nanoparticles for oral delivery of insulin","volume":"425","author":"Wu","year":"2012","journal-title":"Int. J. Pharm."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.biomaterials.2011.10.075","article-title":"Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport","volume":"33","author":"Jin","year":"2012","journal-title":"Biomaterials"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study","volume":"314","author":"Cohn","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/bmj.3.5720.440","article-title":"Treatment of hypertension with clonidine","volume":"3","author":"MacDougall","year":"1970","journal-title":"Br. Med. J."},{"key":"ref_73","first-page":"CD003893","article-title":"Methyldopa for primary hypertension","volume":"4","author":"Mah","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"\u03b2-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.athoracsur.2004.05.046","article-title":"Role of angiotensin-converting enzyme inhibitors in the coronary artery bypass patient","volume":"79","author":"Lazar","year":"2005","journal-title":"Ann. Thorac. Surg."},{"key":"ref_76","first-page":"S9","article-title":"Valsartan after myocardial infarction","volume":"14","year":"2014","journal-title":"Anadolu Kardiyol. Derg."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition","volume":"133","author":"Hubers","year":"2016","journal-title":"Circulation"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e000473","DOI":"10.1136\/openhrt-2016-000473","article-title":"Amlodipine in hypertension: A first-line agent with efficacy for improving blood pressure and patient outcomes","volume":"3","author":"Fares","year":"2016","journal-title":"Open Heart"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40119-016-0059-1","article-title":"Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases","volume":"5","year":"2016","journal-title":"Cardiol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/2040622318784556","article-title":"The therapeutic role of ivabradine in heart failure","volume":"9","author":"Jennings","year":"2018","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5694\/j.1326-5377.2003.tb05445.x","article-title":"Digoxin in heart failure and cardiac arrhythmias","volume":"179","author":"Campbell","year":"2003","journal-title":"Med. J. Aust."},{"key":"ref_84","first-page":"631","article-title":"Statin Therapy: Review of Safety and Potential Side Effects","volume":"32","author":"Ramkumar","year":"2016","journal-title":"Acta Cardiol. Sin."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archinte.163.10.1145","article-title":"Aspirin and clopidogrel in acute coronary syndromes: Therapeutic insights from the CURE study","volume":"163","author":"Jneid","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2147\/vhrm.2006.2.4.379","article-title":"Clinical update on the therapeutic use of clopidogrel: Treatment of acute ST-segment elevation myocardial infarction (STEMI)","volume":"2","author":"Tran","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.cjca.2019.04.026","article-title":"Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial","volume":"35","author":"Welsh","year":"2019","journal-title":"Can. J. Cardiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2217\/nnm.10.126","article-title":"Self-nanoemulsifying drug delivery systems: Formulation insights, applications and advances","volume":"5","author":"Date","year":"2010","journal-title":"Nanomedicine"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejps.2011.04.011","article-title":"Intestinal absorption and intestinal lymphatic transport of sirolimus from self-microemulsifying drug delivery systems assessed using the single-pass intestinal perfusion (SPIP) technique and a chylomicron flow blocking approach: Linear correlation with oral bioavailabilities in rats","volume":"43","author":"Sun","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1208\/s12249-015-0388-8","article-title":"Pharmacokinetic evaluation of improved oral bioavailability of valsartan: Proliposomes versus self-nanoemulsifying drug delivery system","volume":"17","author":"Nekkanti","year":"2016","journal-title":"AAPS PharmSciTech"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejpb.2006.10.014","article-title":"Development and bioavailability assessment of ramipril nanoemulsion formulation","volume":"66","author":"Shafiq","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3109\/03639045.2010.550050","article-title":"Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability","volume":"37","author":"Chhabra","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.msec.2013.10.038","article-title":"Improvement in antihypertensive and antianginal effects of felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design","volume":"35","author":"Shah","year":"2014","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.3109\/03639045.2015.1024685","article-title":"Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design","volume":"41","author":"Dudhipala","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.colsurfb.2013.12.012","article-title":"Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride","volume":"116","author":"Ranpise","year":"2014","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.lfs.2016.08.016","article-title":"A novel nanoproliposomes of lercanidipine: Development, in vitro and preclinical studies to support its effectiveness in hypertension therapy","volume":"162","author":"Deshpande","year":"2016","journal-title":"Life Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/sj.bjp.0700910","article-title":"The antihypertensive effect of orally administered nifedipine-loaded nanoparticles in spontaneously hypertensive rats","volume":"120","author":"Kim","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pop.2012.11.003","article-title":"Hyperlipidemia as a risk factor for cardiovascular disease","volume":"40","author":"Nelson","year":"2013","journal-title":"Prim. Care Clin. Off. Pract."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"212534","DOI":"10.7573\/dic.212534","article-title":"Adding ezetimibe to statin therapy: Latest evidence and clinical implications","volume":"7","author":"Vavlukis","year":"2018","journal-title":"Drugs Context"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/nano.2006.1.2.129","article-title":"Fenofibrate: A novel formulation (Triglide) in the treatment of lipid disorders: A review","volume":"1","author":"Tziomalos","year":"2006","journal-title":"Int. J. Nanomed."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"120077","DOI":"10.1016\/j.ijpharm.2020.120077","article-title":"Enhancement of atorvastatin oral bioavailability via encapsulation in polymeric nanoparticles","volume":"592","author":"Shaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"16105","DOI":"10.1038\/s41598-019-52645-0","article-title":"Surface stabilized atorvastatin nanocrystals with improved bioavailability, safety and antihyperlipidemic potential","volume":"9","author":"Sharma","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"16520","DOI":"10.1039\/C5RA26674B","article-title":"Atorvastatin calcium loaded PCL nanoparticles: Development, optimization, in vitro and in vivo assessments","volume":"6","author":"Kumar","year":"2016","journal-title":"RSC Adv."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1080\/10717544.2017.1337823","article-title":"Atorvastatin-loaded nanostructured lipid carriers (NLCs): Strategy to overcome oral delivery drawbacks","volume":"24","author":"Elmowafy","year":"2017","journal-title":"Drug Deliv."},{"key":"ref_105","first-page":"18","article-title":"Enhanced oral bioavailability of atorvastatin via oil-in-water nanoemulsion using aqueous titration method","volume":"5","author":"Jain","year":"2013","journal-title":"J. Pharm. Sci. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijpharm.2011.05.044","article-title":"Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: Comparative analysis of characteristics, pharmacokinetics and tissue uptake","volume":"415","author":"Tiwari","year":"2011","journal-title":"Int. J. Pharm."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejpb.2016.10.022","article-title":"Improved anti-hyperlipidemic activity of Rosuvastatin Calcium via lipid nanoparticles: Pharmacokinetic and pharmacodynamic evaluation","volume":"110","author":"Dudhipala","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_108","first-page":"5797","article-title":"Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers","volume":"10","author":"Fahmy","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijpharm.2009.04.022","article-title":"Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt","volume":"376","author":"Chen","year":"2009","journal-title":"Int. J. Pharm."},{"key":"ref_110","first-page":"2829","article-title":"Development of self-nanoemulsifying drug delivery systems for the enhancement of solubility and oral bioavailability of fenofibrate, a poorly water-soluble drug","volume":"11","author":"Mohsin","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1208\/s12249-014-0175-y","article-title":"Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement","volume":"15","author":"Tran","year":"2014","journal-title":"AAPS Pharmscitech"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Agrawal, Y.O., Mahajan, U.B., Agnihotri, V.V., Nilange, M.S., Mahajan, H.S., Sharma, C., Ojha, S., Patil, C.R., and Goyal, S.N. (2021). Ezetimibe-Loaded Nanostructured Lipid Carrier Based Formulation Ameliorates Hyperlipidaemia in an Experimental Model of High Fat Diet. Molecules, 26.","DOI":"10.3390\/molecules26051485"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.colsurfb.2012.05.019","article-title":"Optimized self nano-emulsifying systems of ezetimibe with enhanced bioavailability potential using long chain and medium chain triglycerides","volume":"100","author":"Bandyopadhyay","year":"2012","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"101211","DOI":"10.1016\/j.jddst.2019.101211","article-title":"Solidified nanostructured lipid carrier (S-NLC) for enhancing the oral bioavailability of ezetimibe","volume":"53","author":"Shevalkar","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2005.05.006","article-title":"Subcutaneous drug delivery and the role of the lymphatics","volume":"2","author":"McLennan","year":"2005","journal-title":"Drug Discov. Today Technol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc20-S002","article-title":"2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2337\/ds16-0026","article-title":"Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes","volume":"30","author":"Hinnen","year":"2017","journal-title":"Diabetes Spectr."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Roesti, E.S., Boyle, C.N., Zeman, D.T., Sande-Melon, M., Storni, F., Cabral-Miranda, G., Knuth, A., Lutz, T.A., Vogel, M., and Bachmann, M.F. (2020). Vaccination against amyloidogenic aggregates in pancreatic islets prevents development of type 2 diabetes mellitus. Vaccines, 8.","DOI":"10.3390\/vaccines8010116"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.lfs.2017.11.021","article-title":"Therapeutic vaccine against IL-1\u03b2 improved glucose control in a mouse model of type 2 diabetes","volume":"192","author":"Zhang","year":"2018","journal-title":"Life Sci."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Zha, J., Chi, X.-W., Yu, X.-L., Liu, X.-M., Liu, D.-Q., Zhu, J., Ji, H., and Liu, R.-T. (2016). Interleukin-1\u03b2-targeted vaccine improves glucose control and \u03b2-cell function in a diabetic KK-Ay mouse model. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154298"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/mt.2015.227","article-title":"Development of an interleukin-1\u03b2 vaccine in patients with type 2 diabetes","volume":"24","author":"Timper","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"E1256","DOI":"10.1073\/pnas.1322009111","article-title":"Therapeutic vaccine against DPP4 improves glucose metabolism in mice","volume":"111","author":"Pang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Qiu, Z., Chen, X., Zhou, Y., Lin, J., Ding, D., Yang, S., Chen, F., Wang, M., Zhu, F., and Yu, X. (2013). Therapeutic vaccines against human and rat renin in spontaneously hypertensive rats. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066420"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1042\/CS20030381","article-title":"Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects","volume":"107","author":"Brown","year":"2004","journal-title":"Clin. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijcard.2009.10.027","article-title":"A vaccine for hypertension based on peptide AngI-R: A pilot study","volume":"148","author":"Hong","year":"2011","journal-title":"Int. J. Cardiol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/HYPERTENSIONAHA.112.201020","article-title":"Effectiveness and safety of a therapeutic vaccine against angiotensin II receptor type 1 in hypertensive animals","volume":"61","author":"Chen","year":"2013","journal-title":"Hypertension"},{"key":"ref_127","first-page":"107","article-title":"Target organ protection from a novel angiotensin II receptor (AT1) vaccine ATR12181 in spontaneously hypertensive rats","volume":"3","author":"Zhu","year":"2006","journal-title":"Cell. Mol. Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(08)60381-5","article-title":"Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: A double-blind, randomised, placebo-controlled phase IIa study","volume":"371","author":"Tissot","year":"2008","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"43920","DOI":"10.1038\/srep43920","article-title":"A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction","volume":"7","author":"Watanabe","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"9416","DOI":"10.1021\/acsnano.5b04137","article-title":"Celecoxib nanoparticles for therapeutic angiogenesis","volume":"9","author":"Margulis","year":"2015","journal-title":"ACS Nano"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.colsurfb.2017.10.033","article-title":"Injectable deferoxamine nanoparticles loaded chitosan-hyaluronic acid coacervate hydrogel for therapeutic angiogenesis","volume":"161","author":"Vignesh","year":"2018","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/14712598.2017.1305354","article-title":"Alirocumab for the treatment of hypercholesterolemia","volume":"17","author":"Tomlinson","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor","volume":"57","author":"Kasichayanula","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/ATVBAHA.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein (a) in various populations with hypercholesterolemia: Results of 4 phase III trials. Arterioscler","volume":"35","author":"Santos","year":"2015","journal-title":"Thromb. Vasc. Biol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein (a) in people with raised lipoprotein (a): Two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"ref_139","unstructured":"Pharma, I. (2020). Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) at ESC Congress 2020, Ionis Pharma."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Kawakami, R., Nozato, Y., Nakagami, H., Ikeda, Y., Shimamura, M., Yoshida, S., Sun, J., Kawano, T., Takami, Y., and Noma, T. (2018). Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin\/kexin type 9 (PCSK9) epitope in mice. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0191895"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","article-title":"The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE* 3Leiden. CETP mice","volume":"38","author":"Landlinger","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","article-title":"A cholesterol-lowering VLP vaccine that targets PCSK9","volume":"33","author":"Crossey","year":"2015","journal-title":"Vaccine"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/hr.2013.155","article-title":"Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension","volume":"37","author":"Olearczyk","year":"2014","journal-title":"Hypertens. Res."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Hsu, C.-N., and Tain, Y.-L. (2021). Targeting the Renin\u2013Angiotensin\u2013Aldosterone System to Prevent Hypertension and Kidney Disease of Developmental Origins. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052298"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/jvim.15454","article-title":"The renin-angiotensin-aldosterone system and its suppression","volume":"33","author":"Ames","year":"2019","journal-title":"J. Vet. Intern. Med."},{"key":"ref_147","unstructured":"U.S. Food and Drug Administration (2021, May 01). Kynamro (Mipomersen Sodium) Injection: Drug Approval Package, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/203568Orig1s000TOC.cfm."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40265-019-01114-z","article-title":"Efficacy and safety of mipomersen: A systematic review and meta-analysis of randomized clinical trials","volume":"79","author":"Fogacci","year":"2019","journal-title":"Drugs"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40262-014-0224-4","article-title":"Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (Kynamro\u00ae): A second-generation antisense oligonucleotide inhibitor of apolipoprotein B","volume":"54","author":"Geary","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/eurheartj\/eht549","article-title":"Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension","volume":"36","author":"Santos","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2147\/DDDT.S224771","article-title":"Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy","volume":"14","author":"Esan","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_152","unstructured":"European Medicines Agency (2021, April 01). Waylivra (Volanesorsen): Public Assessment Report, Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/waylivra."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_154","unstructured":"European Medicines Agency (2021, May 01). Waylivra, INN-Volanesorsen, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/waylivra-epar-public-assessment-report_en.pdf."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacl.2019.11.001","article-title":"Inclisiran\u2014New hope in the management of lipid disorders?","volume":"14","author":"Penson","year":"2020","journal-title":"J. Clin. Lipidol."},{"key":"ref_156","unstructured":"European Medicines Agency (2021, May 01). Leqvio (Inclisiran): An Overview of Leqvio and Why It Is Authorised in the EU, Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/leqvio."},{"key":"ref_157","unstructured":"European Medicines Agency (2021, May 01). Leqvio: Assessment Report, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/leqvio-epar-public-assessment-report_en.pdf."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Fowler, A., Sampson, M., Remaley, A.T., and Chackerian, B. (2021). A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice. bioRxiv.","DOI":"10.1101\/2021.03.08.434130"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41569-018-0087-8","article-title":"Cardiac lymphatics in health and disease","volume":"16","author":"Brakenhielm","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Ananthakrishnan, P., Mariani, G., Moresco, L., and Giuliano, A.E. (2008). The anatomy and physiology of lymphatic circulation. Radioguided Surgery, Springer.","DOI":"10.1007\/978-0-387-38327-9_7"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1015880819328","article-title":"Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration","volume":"7","author":"Supersaxo","year":"1990","journal-title":"Pharm. Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jps.2600740902","article-title":"Lymphatic transport of liposome-encapsulated agents: Effects of liposome size following intraperitoneal administration","volume":"74","author":"Hirano","year":"1985","journal-title":"J. Pharm. Sci."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"H15","DOI":"10.1152\/ajpheart.1985.248.1.H15","article-title":"Exchange of macromolecules between peritoneal cavity and plasma","volume":"248","author":"Flessner","year":"1985","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.cmet.2013.04.002","article-title":"Lymphatic vessels are essential for the removal of cholesterol from peripheral tissues by SR-BI-mediated transport of HDL","volume":"17","author":"Lim","year":"2013","journal-title":"Cell Metab."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2006.01.006","article-title":"In vivo targeting of dendritic cells in lymph nodes with poly (propylene sulfide) nanoparticles","volume":"112","author":"Reddy","year":"2006","journal-title":"J. Control. Release"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11095-010-0123-9","article-title":"Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs","volume":"28","author":"Harvey","year":"2011","journal-title":"Pharm. Res."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Hettinga, J., and Carlisle, R. (2020). Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects. Vaccines, 8.","DOI":"10.3390\/vaccines8030534"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1146\/annurev-fluid-122316-045259","article-title":"Lymphatic System Flows","volume":"50","author":"Moore","year":"2018","journal-title":"Annu. Rev. Fluid Mech."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1089\/lrb.2013.0012","article-title":"Lymphatic Function and Immune Regulation in Health and Disease","volume":"11","author":"Liao","year":"2013","journal-title":"Lymphat. Res. Biol."},{"key":"ref_170","first-page":"22","article-title":"Intradermal Therapy (mesotherapy) in Dermatology","volume":"2","author":"Canzona","year":"2020","journal-title":"J. Dermatol. Ski. Sci."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"a2052","DOI":"10.1136\/bmj.a2052","article-title":"Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: Randomised trial","volume":"337","author":"Hawkridge","year":"2008","journal-title":"BMJ"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3389\/fimmu.2018.01891","article-title":"Therapies to suppress \u03b2 cell autoimmunity in type 1 diabetes","volume":"9","author":"Kroger","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.3389\/fimmu.2017.01898","article-title":"Type 1 diabetes: A chronic anti-self-inflammatory response","volume":"8","author":"Clark","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Richardson, S.J., Willcox, A., Bone, A.J., Morgan, N.G., and Foulis, A.K. (2011). Immunopathology of the human pancreas in type-I diabetes. Seminars in Immunopathology, Springer.","DOI":"10.1007\/s00281-010-0205-0"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4161\/hv.1.4.1923","article-title":"The prospect of vaccination to prevent type 1 diabetes","volume":"1","author":"Harrison","year":"2005","journal-title":"Hum. Vaccines"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3389\/fimmu.2018.00392","article-title":"Peptide immunotherapy for type 1 diabetes\u2014Clinical advances","volume":"9","author":"Smith","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2249.2008.03814.x","article-title":"Proinsulin peptide immunotherapy in type 1 diabetes: Report of a first-in-man Phase I safety study","volume":"155","author":"Thrower","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijpharm.2019.03.041","article-title":"Conjugation of a peptide autoantigen to gold nanoparticles for intradermally administered antigen specific immunotherapy","volume":"562","author":"Dul","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S2213-8587(20)30104-2","article-title":"Safety and feasibility of intradermal injection with tolerogenic dendritic cells pulsed with proinsulin peptide\u2014For type 1 diabetes","volume":"8","author":"Nikolic","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/apnr.2002.34142","article-title":"Intramuscular injection: An integrative research review and guideline for evidence-based practice","volume":"15","author":"Nicoll","year":"2002","journal-title":"Appl. Nurs. Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1080\/21645515.2017.1334747","article-title":"Establishing a new appropriate intramuscular injection site in the deltoid muscle","volume":"13","author":"Nakajima","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"52","DOI":"10.7748\/ns.29.4.52.e9183","article-title":"Intramuscular injection technique: An evidence-based approach","volume":"29","year":"2014","journal-title":"Nurs. Stand."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1046\/j.1365-2648.2000.01312.x","article-title":"Drawing up and administering intramuscular injections: A review of the literature","volume":"31","author":"Rodger","year":"2000","journal-title":"J. Adv. Nurs."},{"key":"ref_184","first-page":"31","article-title":"Localisation of lymphatic vessels and vascular endothelial growth factors-C and -D in human and mouse skeletal muscle with immunohistochemistry","volume":"127","author":"Havas","year":"2007","journal-title":"Histochem. Cell Biol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1089\/10430349950016672","article-title":"Insulin delivery with plasmid DNA","volume":"10","author":"Abai","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1093\/eurheartj\/ehr004","article-title":"Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome","volume":"32","author":"Phrommintikul","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ehj.2003.10.018","article-title":"Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) study","volume":"25","author":"Gurfinkel","year":"2004","journal-title":"Eur. Heart J."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/2047487314549512","article-title":"Association between pneumococcal vaccination and cardiovascular outcomes: A systematic review and meta-analysis of cohort studies","volume":"22","author":"Vlachopoulos","year":"2015","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"887","DOI":"10.4161\/hv.27537","article-title":"Obesity vaccines","volume":"10","author":"Monteiro","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13410-020-00819-2","article-title":"RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020","volume":"40","author":"Chawla","year":"2020","journal-title":"Int. J. Diabetes Dev. Ctries."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/eurheartj\/ehw019","article-title":"Gene therapy for the treatment of heart failure: Promise postponed","volume":"37","author":"Hulot","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10741-008-9132-8","article-title":"\u03b2-Adrenergic stimulation and myocardial function in the failing heart","volume":"14","author":"Eschenhagen","year":"2009","journal-title":"Heart Fail. Rev."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1073\/pnas.95.12.7000","article-title":"Expression of a \u03b2-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice","volume":"95","author":"Rockman","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"5809","DOI":"10.1073\/pnas.091102398","article-title":"Cardiac \u03b2ARK1 inhibition prolongs survival and augments \u03b2 blocker therapy in a mouse model of severe heart failure","volume":"98","author":"Harding","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.CIR.103.9.1311","article-title":"In vivo ventricular gene delivery of a \u03b2-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction","volume":"103","author":"Shah","year":"2001","journal-title":"Circulation"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1161\/CIRCULATIONAHA.108.803999","article-title":"Clinical Perspective","volume":"119","author":"Rengo","year":"2009","journal-title":"Circulation"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1161\/hc4201.097188","article-title":"Ventricular dysfunction after cardioplegic arrest is improved after myocardial gene transfer of a \u03b2-adrenergic receptor kinase inhibitor","volume":"104","author":"Tevaearai","year":"2001","journal-title":"Circulation"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/eurheartj\/ehr447","article-title":"\u03b2ARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model","volume":"34","author":"Raake","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jacc.2007.12.014","article-title":"Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure","volume":"51","author":"Kawase","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_200","first-page":"362","article-title":"SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure","volume":"4","author":"Lyon","year":"2011","journal-title":"Circulation"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): A randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/mt.2012.194","article-title":"Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European union","volume":"20","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_203","unstructured":"Burnett, J.R., Hooper, A.J., and Hegele, R.A. (2017). Familial Lipoprotein Lipase Deficiency."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1089\/hum.2005.16.1276","article-title":"Gene therapy for lipoprotein lipase deficiency: Working toward clinical application","volume":"16","author":"Rip","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/humc.2013.087","article-title":"Lessons learned from the clinical development and market authorization of Glybera","volume":"24","author":"Bryant","year":"2013","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Senior, M. (2017). After Glybera\u2019s Withdrawal, What\u2019s Next for Gene Therapy?, Nature Publishing Group.","DOI":"10.1038\/nbt0617-491"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1161\/CIRCRESAHA.111.252981","article-title":"Gene therapy for heart failure","volume":"110","author":"Tilemann","year":"2012","journal-title":"Circ. Res."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jacbts.2017.02.005","article-title":"Cardiac Lymphatic Vessels, Transport, and Healing of the Infarcted Heart","volume":"2","author":"Huang","year":"2017","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamacardio.2016.0008","article-title":"Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: A randomized clinical trial","volume":"1","author":"Hammond","year":"2016","journal-title":"JAMA Cardiol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","article-title":"Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID) a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure","volume":"124","author":"Jessup","year":"2011","journal-title":"Circulation"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/ejhf.826","article-title":"Effect of intracoronary administration of AAV1\/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: Results from the AGENT-HF randomized phase 2 trial","volume":"19","author":"Hulot","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_212","unstructured":"Precigen Triple-Gene (2021, April 01). Precigen Triple-Gene Provides Six-Month Follow-Up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart Failure. Available online: https:\/\/www.prnewswire.com\/news-releases\/precigen-triple-gene-provides-six-month-follow-up-data-from-phase-i-study-of-inxn-4001-a-multigenic-investigational-therapeutic-candidate-for-heart-failure-301107258.html."},{"key":"ref_213","first-page":"1","article-title":"425. Arginine and Tetrahydrobiopterin Synergistically Potentiate the Antirestenotic Effect of Vascular Gene Therapy with Inducible Nitric Oxide Synthase","volume":"18","author":"Model","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1093\/eurheartj\/ehv254","article-title":"Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: The STOP-HF randomized Phase II trial","volume":"36","author":"Chung","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_215","unstructured":"Juventas Therapeutics (2021, May 01). Juventas Therapeutics Completes Enrollment of Phase I\/II RETRO-HF Trial and Demonstrates Safety for Retrograde Infusion of JVS-100 in Patients with Heart Failure. Available online: https:\/\/www.prnewswire.com\/news-releases\/juventas-therapeutics-completes-enrollment-of-phase-iii-retro-hf-trial-and-demonstrates-safety-for-retrograde-infusion-of-jvs-100-in-patients-with-heart-failure-270890361.html."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.omtm.2020.05.030","article-title":"Synthetic mRNA encoding VEGF-A in patients undergoing coronary artery bypass grafting: Design of a phase 2a clinical trial","volume":"18","author":"Anttila","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41467-019-08852-4","article-title":"Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes","volume":"10","author":"Gan","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/mt.2014.127","article-title":"Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure","volume":"22","author":"Ishikawa","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/gt.2012.87","article-title":"Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: Phase I clinical study","volume":"20","author":"Kim","year":"2013","journal-title":"Gene Ther."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1093\/eurheartj\/ehx352","article-title":"Adenoviral intramyocardial VEGF-D\u0394N\u0394C gene transfer increases myocardial perfusion reserve in refractory angina patients: A phase I\/IIa study with 1-year follow-up","volume":"38","author":"Hartikainen","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_221","first-page":"4605","article-title":"Ad-HGF improves the cardiac remodeling of rat following myocardial infarction by upregulating autophagy and necroptosis and inhibiting apoptosis","volume":"8","author":"Liu","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1089\/hum.2015.119","article-title":"Effects of adenovirus-mediated hepatocyte growth factor gene therapy on postinfarct heart function: Comparison of single and repeated injections","volume":"27","author":"Wang","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1021\/nn5061404","article-title":"Nanoparticle-mediated dual delivery of an antioxidant and a peptide against the L-Type Ca2+ channel enables simultaneous reduction of cardiac ischemia-reperfusion injury","volume":"9","author":"Hardy","year":"2015","journal-title":"ACS Nano"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1210\/jc.2011-3002","article-title":"Effect of alipogene tiparvovec (AAV1-LPLS447X) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients","volume":"97","author":"Carpentier","year":"2012","journal-title":"J. Clin. Endocrinol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"e10143","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the clinic: An update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"7156","DOI":"10.1038\/s41598-017-07524-x","article-title":"Dynamics of angiogenesis in ischemic areas of the infarcted heart","volume":"7","author":"Kobayashi","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"R494","DOI":"10.1152\/ajpregu.00460.2005","article-title":"Adenoviral PR39 improves blood flow and myocardial function in a pig model of chronic myocardial ischemia by enhancing collateral formation","volume":"290","author":"Post","year":"2006","journal-title":"Am. J. Physiol. -Regul. Integr. Comp. Physiol."},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Du, C., Chen, X.-W., Wang, Z.-M., Meng, H.-Y., Li, Y.-F., Wei, T.-W., and Wang, L.-S. (2020). HGF Treatment Promotes Cardiac Function and Cardiac Repair: Meta-analysis of Pig Models with Myocardial Infarction. Res. Sq., preprint.","DOI":"10.21203\/rs.3.rs-34290\/v1"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1161\/CIRCRESAHA.108.182287","article-title":"VEGF-A and PDGF-B combination gene therapy prolongs angiogenic effects via recruitment of interstitial mononuclear cells and paracrine effects rather than improved pericyte coverage of angiogenic vessels","volume":"103","author":"Korpisalo","year":"2008","journal-title":"Circ. Res."},{"key":"ref_230","first-page":"923","article-title":"The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection","volume":"9","author":"Jin","year":"2015","journal-title":"Patient Prefer. Adherence"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/B978-0-444-81871-3.50007-2","article-title":"2\u2014Intravenous Drug Administration","volume":"Volume 12","author":"Claassen","year":"1994","journal-title":"Techniques in the Behavioral and Neural Sciences"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1517\/17425240903085128","article-title":"Drug delivery to the lymphatic system: Importance in future cancer diagnosis and therapies","volume":"6","author":"Xie","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1002\/jps.23211","article-title":"Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: Implications for lymphatic transport and absolute bioavailability studies","volume":"101","author":"Caliph","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2017.12.031","article-title":"Distribution of therapeutic proteins into thoracic lymph after intravenous administration is protein size-dependent and primarily occurs within the liver and mesentery","volume":"272","author":"Yadav","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.freeradbiomed.2010.04.034","article-title":"Sustained release nitric oxide from long-lived circulating nanoparticles","volume":"49","author":"Cabrales","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ejhf.463","article-title":"A specifically designed nanoconstruct associates, internalizes, traffics in cardiovascular cells, and accumulates in failing myocardium: A new strategy for heart failure diagnostics and therapeutics","volume":"18","author":"Youker","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"20180236","DOI":"10.1098\/rsif.2018.0236","article-title":"A combined low-frequency electromagnetic and fluidic stimulation for a controlled drug release from superparamagnetic calcium phosphate nanoparticles: Potential application for cardiovascular diseases","volume":"15","author":"Marrella","year":"2018","journal-title":"J. R. Soc. Interface"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.2217\/nnm.15.126","article-title":"Bioactive nanoparticles improve calcium handling in failing cardiac myocytes","volume":"10","author":"Maxwell","year":"2015","journal-title":"Nanomedicine"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.hrthm.2012.05.011","article-title":"Cell-specific nanoplatform-enabled photodynamic therapy for cardiac cells","volume":"9","author":"Avula","year":"2012","journal-title":"Heart Rhythm."},{"key":"ref_240","first-page":"87","article-title":"Anticoagulant Therapy for Acute Coronary Syndromes","volume":"13","author":"Onwordi","year":"2018","journal-title":"Interv. Cardiol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.biomaterials.2017.03.001","article-title":"A VEGF delivery system targeting MI improves angiogenesis and cardiac function based on the tropism of MSCs and layer-by-layer self-assembly","volume":"127","author":"Liu","year":"2017","journal-title":"Biomaterials"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1161\/CIRCULATIONAHA.112.000116","article-title":"Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice","volume":"127","author":"Majmudar","year":"2013","journal-title":"Circulation"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.biomaterials.2017.11.012","article-title":"Improved heart repair upon myocardial infarction: Combination of magnetic nanoparticles and tailored magnets strongly increases engraftment of myocytes","volume":"155","author":"Ottersbach","year":"2018","journal-title":"Biomaterials"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jconrel.2013.04.022","article-title":"Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction","volume":"170","author":"Chang","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Nagaoka, K., Matoba, T., Mao, Y., Nakano, Y., Ikeda, G., Egusa, S., Tokutome, M., Nagahama, R., Nakano, K., and Sunagawa, K. (2015). A new therapeutic modality for acute myocardial infarction: Nanoparticle-mediated delivery of pitavastatin induces cardioprotection from ischemia-reperfusion injury via activation of PI3K\/Akt pathway and anti-inflammation in a rat model. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0132451"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/hum.2012.108","article-title":"Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia","volume":"24","author":"Kassim","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1089\/humc.2017.007","article-title":"Nonclinical pharmacology\/toxicology study of AAV8. TBG. mLDLR and AAV8. TBG. hLDLR in a mouse model of homozygous familial hypercholesterolemia","volume":"28","author":"Greig","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1073\/pnas.80.4.1068","article-title":"In vivo expression of rat insulin after intravenous administration of the liposome-entrapped gene for rat insulin I","volume":"80","author":"Nicolau","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/sj.gt.3301544","article-title":"Adenoviral vector-mediated insulin gene transfer in the mouse pancreas corrects streptozotocin-induced hyperglycemia","volume":"8","author":"Shifrin","year":"2001","journal-title":"Gene Ther."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2337\/db05-1615","article-title":"Reversal of type 1 diabetes by engineering a glucose sensor in skeletal muscle","volume":"55","author":"Mas","year":"2006","journal-title":"Diabetes"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.diabres.2005.08.005","article-title":"Gene therapy for diabetes mellitus in rats by intramuscular injection of lentivirus containing insulin gene","volume":"71","author":"Oh","year":"2006","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1210\/mend.11.6.0017","article-title":"Hepatic insulin gene expression as treatment for type 1 diabetes mellitus in rats","volume":"11","author":"Muzzin","year":"1997","journal-title":"Mol. Endocrinol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/sj.gt.3301297","article-title":"Regulated hepatic insulin gene therapy of STZ-diabetic rats","volume":"7","author":"Thule","year":"2000","journal-title":"Gene Ther."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/jgm.708","article-title":"Safety and efficacy of adeno-associated viral vector-mediated insulin gene transfer via portal vein to the livers of streptozotocin-induced diabetic Sprague-Dawley rats","volume":"7","author":"Park","year":"2005","journal-title":"J. Gene Med."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1126\/science.290.5498.1959","article-title":"Glucose-dependent insulin release from genetically engineered K cells","volume":"290","author":"Cheung","year":"2000","journal-title":"Science"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4067\/S0716-97602011000300012","article-title":"Insulin is secreted upon glucose stimulation by both gastrointestinal enteroendocrine K-cells and L-cells engineered with the preproinsulin gene","volume":"44","author":"Encina","year":"2011","journal-title":"Biol. Res."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/jgm.2835","article-title":"Long-term glycemic control with hepatic insulin gene therapy in streptozotocin-diabetic mice","volume":"17","author":"Campbell","year":"2015","journal-title":"J. Gene Med."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.4049\/jimmunol.158.6.2947","article-title":"CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice","volume":"158","author":"Chatenoud","year":"1997","journal-title":"J. Immunol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4049\/jimmunol.168.2.933","article-title":"Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance","volume":"168","author":"Coon","year":"2002","journal-title":"J. Immunol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"346","author":"Herold","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.2337\/db13-0345","article-title":"Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders","volume":"62","author":"Herold","year":"2013","journal-title":"Diabetes"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/diabetes.54.6.1763","article-title":"A single course of anti-CD3 monoclonal antibody hOKT3\u03b31 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes","volume":"54","author":"Herold","year":"2005","journal-title":"Diabetes"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1161\/01.CIR.101.6.682","article-title":"Antisense inhibition of \u03b21-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats","volume":"101","author":"Zhang","year":"2000","journal-title":"Circulation"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"e004028","DOI":"10.1161\/JAHA.116.004028","article-title":"Downregulation of Renal G Protein\u2013Coupled Receptor Kinase Type 4 Expression via Ultrasound-Targeted Microbubble Destruction Lowers Blood Pressure in Spontaneously Hypertensive Rats","volume":"5","author":"Huang","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_266","first-page":"1345","article-title":"Gene therapy for hypertension","volume":"17","author":"Paulis","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1093\/eurheartj\/ehx343","article-title":"Cardiomyocyte renewal in the human heart: Insights from the fall-out","volume":"38","author":"Sadek","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1096\/fasebj.6.9.1612296","article-title":"Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium","volume":"6","author":"Torchilin","year":"1992","journal-title":"FASEB J."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1096\/fj.08-127373","article-title":"Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function","volume":"23","author":"Scott","year":"2009","journal-title":"FASEB J."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/gt.2008.135","article-title":"Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide","volume":"16","author":"Ko","year":"2009","journal-title":"Gene Ther."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.1021\/nl2025882","article-title":"Nanoparticles targeting the infarcted heart","volume":"11","author":"Dvir","year":"2011","journal-title":"Nano Lett."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1007\/s00261-015-0429-5","article-title":"The subperitoneal space and peritoneal cavity: Basic concepts","volume":"40","author":"Pannu","year":"2015","journal-title":"Abdom. Imaging"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11095-019-2745-x","article-title":"Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies?","volume":"37","author":"Archie","year":"2020","journal-title":"Pharm. Res."},{"key":"ref_274","unstructured":"Michailova, K.N., and Usunoff, K.G. (2006). Serosal Membranes (Pleura, Pericardium, Peritoneum): Normal Structure, Development and Experimental Pathology, Springer Science & Business Media."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1021\/acs.molpharmaceut.9b00855","article-title":"Lymphatic Uptake of Liposomes after Intraperitoneal Administration Primarily Occurs via the Diaphragmatic Lymphatics and is Dependent on Liposome Surface Properties","volume":"16","author":"Lee","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000136874","article-title":"Transport of model compounds across the peritoneal membrane in the rat","volume":"17","author":"Torres","year":"1978","journal-title":"Pharmacology"},{"key":"ref_277","first-page":"600","article-title":"Administration of substances to laboratory animals: Routes of administration and factors to consider","volume":"50","author":"Turner","year":"2011","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_280","unstructured":"National Cancer Institute (2021, May 01). NCI Clinical Announcement on Intraperitoneal Chemotherapy for Ovarian Cancer, Available online: https:\/\/ctep.cancer.gov\/highlights\/docs\/clin_annc_010506.pdf."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.2147\/IJN.S129324","article-title":"Methotrexate carried in lipid core nanoparticles reduces myocardial infarction size and improves cardiac function in rats","volume":"12","author":"Guido","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1161\/01.CIR.0000015982.70785.B7","article-title":"Phase 1\/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia","volume":"105","author":"Losordo","year":"2002","journal-title":"Circulation"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1540-8183.2005.04026.x","article-title":"Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patients","volume":"18","author":"Reilly","year":"2005","journal-title":"J. Interv. Cardiol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/8\/1200\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:40:36Z","timestamp":1760164836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/8\/1200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":283,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["pharmaceutics13081200"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13081200","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,4]]}}}